PMID- 36567579
OWN - NLM
STAT- MEDLINE
DCOM- 20221227
LR  - 20230103
IS  - 2095-4352 (Print)
VI  - 34
IP  - 12
DP  - 2022 Dec
TI  - [Short-term effect of HeartCon left ventricular assist device on the treatment of 
      20 adult patients with end-stage heart failure].
PG  - 1258-1262
LID - 10.3760/cma.j.cn121430-20220106-00015 [doi]
AB  - OBJECTIVE: To investigate and evaluate the efficacy of HeartCon left ventricular 
      assist device (LVAD) in the treatment of adult patients with end-stage heart 
      failure (ESHF). METHODS: A prospective and observational study was conducted. 
      Patients with ESHF who underwent LVAD implantation in the department of cardiac 
      surgery of Teda International Cardiovascular Hospital from September 2020 to 
      August 2021 were selected. The left ventricular end-diastolic diameter (LVEDD), 
      left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) 
      classification, N-terminal pro-B type natriuretic peptide (NT-proBNP), and six 
      minute walk distance (6MWD) before operation and 90 days after operation were 
      compared. The incidence of equipment failures and major adverse events within 90 
      days after operation were recorded. RESULTS: A total of 20 patients with ESHF 
      were included, with 15 males and 5 females. Patients' age ranged from 20 to 67 
      years old, with an average of (50.2+/-13.6) years old. The range of body weight was 
      49.8-106.1 kg, with an average of (67.9+/-15.5) kg, and the body surface area (BSA) 
      was from 1.49 to 2.32 m(2), with an average of (17.6+/-0.22) m(2). The operation 
      process of all the patients were successful. The length of hospital stay ranged 
      from 33 to 90 days, and the average was 56.0 (42.8, 75.0) days. Complications 
      within 90 days after operation as follows, 2 cases with pericardial tamponade 
      (10%), 1 case with cerebral hemorrhage (5%), 1 case with mediastinum infection 
      (5%), 3 cases with acute renal injury (AKI, 15%), 5 cases with gastrointestinal 
      bleeding (25%). There were no mechanical failure of LVAD and hemolysis events, 
      right ventricular failure (RVF), cerebral infarction and death occurred. Compared 
      with preoperative, the LVEDD significantly decreased (mm: 67.50+/-13.98 vs. 
      77.40+/-9.73), LVEF significantly increased (%: 34.80+/-9.76 vs. 22.70+/-5.62), 
      NT-proBNP significantly decreased (ng/L: 2 028.65+/-1 752.05 vs. 4 796.45+/-4 
      355.40), 6MWD significantly increased (m: 385.20+/-144.12 vs. 85.81+/-63.50) at 90 
      days after operation, and the differences were statistically significant (all P < 
      0.05). 18 cases (90%) of the 20 patients reached NYHA classification I and 2 
      cases (10%) reached NYHA classification II, which were significantly improved 
      compared with those before surgery (all patients' NYHA classification were IV 
      before surgery). CONCLUSIONS: HeartCon LVAD can effectively improve the life 
      quality of patients with ESHF, which has been proved safe and effective in 
      clinical trials, but its long-term effects and complications need further 
      observation and study.
FAU - Wang, Wei
AU  - Wang W
AD  - Intensive Care Unit, Teda International Cardiovascular Hospital, Tianjin 300457, 
      China.
FAU - Song, Yu
AU  - Song Y
AD  - Department of Cardiac Care Unit, Teda International Cardiovascular Hospital, 
      Tianjin 300457, China.
FAU - Zhang, Yunqiang
AU  - Zhang Y
AD  - Department of Cardiac Care Unit, Teda International Cardiovascular Hospital, 
      Tianjin 300457, China.
FAU - Wang, Zhengqing
AU  - Wang Z
AD  - Department of Cardiac Surgery, Teda International Cardiovascular Hospital, 
      Tianjin 300457, China. Corresponding author: Liu Xiaocheng, Email: 
      liuxc@tedaich.com.
FAU - Liu, Zhigang
AU  - Liu Z
AD  - Department of Cardiac Surgery, Teda International Cardiovascular Hospital, 
      Tianjin 300457, China. Corresponding author: Liu Xiaocheng, Email: 
      liuxc@tedaich.com.
FAU - Li, Shujie
AU  - Li S
AD  - Intensive Care Unit, Teda International Cardiovascular Hospital, Tianjin 300457, 
      China.
FAU - Tang, Yuan
AU  - Tang Y
AD  - Intensive Care Unit, Teda International Cardiovascular Hospital, Tianjin 300457, 
      China.
FAU - Liu, Xiaocheng
AU  - Liu X
AD  - Department of Cardiac Surgery, Teda International Cardiovascular Hospital, 
      Tianjin 300457, China. Corresponding author: Liu Xiaocheng, Email: 
      liuxc@tedaich.com.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Observational Study
PL  - China
TA  - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
JT  - Zhonghua wei zhong bing ji jiu yi xue
JID - 101604552
SB  - IM
MH  - Male
MH  - Female
MH  - Humans
MH  - Adult
MH  - Young Adult
MH  - Middle Aged
MH  - Aged
MH  - Stroke Volume
MH  - Prospective Studies
MH  - *Heart-Assist Devices/adverse effects
MH  - Ventricular Function, Left
MH  - *Heart Failure/therapy/etiology
EDAT- 2022/12/27 06:00
MHDA- 2022/12/28 06:00
CRDT- 2022/12/26 01:53
PHST- 2022/12/26 01:53 [entrez]
PHST- 2022/12/27 06:00 [pubmed]
PHST- 2022/12/28 06:00 [medline]
AID - 10.3760/cma.j.cn121430-20220106-00015 [doi]
PST - ppublish
SO  - Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022 Dec;34(12):1258-1262. doi: 
      10.3760/cma.j.cn121430-20220106-00015.